Sign in

Private company

Histogen Inc.

Histogen Inc. is an American pharmaceutical preparations company based in San Diego.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersSan Diego, United States2
  • Incorporated inDE3
  • Business address10655 Sorrento Valley Road, Suite 200, San Diego, Ca 921213
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300XHWPP338YQ8O672
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 39987162

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-282.4%Operating margin4
-282.4%Net margin4
265.2%Revenue growth, 20224
-73.9%Return on equity4
-$9.9MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$5.0M

Out of $3.8M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$3.8M in 2022+372% since 2016
0$10.0M$20.0M$30.0M$40.0M2016: $799.0K$799.0K20162017: $35.4M$35.4M2017+4328%2018: $33.6M$33.6M2018−5%2019: $11.5M$11.5M2019−66%2020: $2.1M$2.1M2020−82%2021: $1.0M$1.0M2021−50%2022: $3.8M$3.8M2022+265%
Operating income56784-$10.6M in 2022−64% since 2016
-$30.0M-$20.0M-$10.0M02016: -$29.8M-$29.8M20162017: -$17.6M-$17.6M2017−41%2018: -$18.3M-$18.3M2018+4%2019: -$3.3M-$3.3M2019−82%2020: -$18.9M-$18.9M2020+468%2021: -$15.5M-$15.5M2021−18%2022: -$10.6M-$10.6M2022−31%
Net income5684-$10.6M in 2022−64% since 2016
-$30.0M-$20.0M-$10.0M02016: -$29.7M-$29.7M20162017: -$17.4M-$17.4M2017−41%2018: -$18.0M-$18.0M2018+4%2019: -$11.4M-$11.4M2019−37%2020: -$18.8M-$18.8M2020+65%2021: -$15.0M-$15.0M2021−20%2022: -$10.6M-$10.6M2022−29%
Fiscal year2016201720182019202020212022
Revenue$799.0K5$35.4M6$33.6M6$11.5M7$2.1M8$1.0M4$3.8M4
Research and development$20.3M5$43.2M6$41.4M6$4.1M7$6.2M8$8.5M4$5.0M4
Operating expenses$16.5M4$14.4M4
Operating income-$29.8M5-$17.6M6-$18.3M6-$3.3M7-$18.9M8-$15.5M4-$10.6M4
Interest$70.0K5$662.0K6$696.0K6$06
Income tax$07$08$04$04
Net income-$29.7M5-$17.4M6-$18.0M6-$11.4M6-$18.8M8-$15.0M4-$10.6M4
Earnings per share-$7.794-$3.464
Earnings per share (diluted)-$7.794-$3.464
Shares (weighted, basic)1.9M shares43.2M shares4
Shares (weighted, diluted)1.9M shares43.2M shares4

Compare Histogen Inc. with another company

Corporate structure

Histogen Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Histogen Inc.

  • Histogen Inc. San Diego, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Histogen Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.2M4 Dec 31, 2022$1.0M4 Dec 31, 2021+17.1%
Accumulated depreciation$774.0K4 Dec 31, 2022$634.0K4 Dec 31, 2021+22.1%
Property and equipment, net$436.0K4 Dec 31, 2022$399.0K4 Dec 31, 2021+9.3%
Finance-lease assets$12.0K4 Dec 31, 2022$20.0K4 Dec 31, 2021−40.0%
Operating-lease assets (leased space)$4.7M4 Dec 31, 2022$4.4M4 Dec 31, 2021+5.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$12.1M4 Dec 31, 2022$18.7M4 Dec 31, 2021−35.2%

Leadership

Who has led Histogen Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steven J. Mento2013–2023
  2. Richard W. Pascoe2020–2021

President

  1. Steven J. Mento2013–2023
  2. Richard W. Pascoe2020–2021

Chief financial officer

  1. Charles Cashion2013–2017
  2. Keith W. Marshall2017–2020
  3. Susan A. Knudson2021–2023

Chief operating officer

  1. Keith W. Marshall2017–2020
  2. Susan A. Knudson2023
201520202025
Board members and other officers (29)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJonathan H. Jackson named Jul 26, 202245

Former names

  • Conatus Pharmaceuticals Inc.Aug 13, 2014 to May 21, 20203
  • Conatus Pharmaceuticals IncNov 30, 2006 to Jun 23, 20143

Timeline

  1. Dec 14, 20238-K Shareholder vote; Regulation FD disclosure46
  2. Dec 5, 20238-K Shareholder vote; Regulation FD disclosure; Other events47
  3. Oct 3, 20238-K Entered a material agreement; Ended a material agreement48
  4. Sep 26, 20238-K Listing notice or transfer49
  5. Sep 18, 20238-K Executive or director change; Other events50
  6. Aug 15, 20238-K Change of auditor51
  7. Jul 5, 20238-K Other events52
  8. Jun 21, 20238-K Shareholder vote53
  9. Jun 5, 20238-K Listing notice or transfer54
  10. May 11, 20238-K Results of operations55
  11. Apr 3, 20238-K Entered a material agreement; Other events56
  12. Mar 14, 20238-K Executive or director change57
  13. Dec 7, 2020New chief executive Richard W. Pascoe becomes CEO12
  14. Jul 24, 2013New chief executive Steven J. Mento becomes CEO13
  15. Jul 13, 2005Founded Histogen Inc. is founded2

Calendar

When it reported results

  1. May 11, 2023Reported quarterly or annual results55
  2. Mar 9, 2023Reported quarterly or annual results58
  3. Nov 10, 2022Reported quarterly or annual results59
  4. Aug 11, 2022Reported quarterly or annual results60
  5. May 12, 2022Reported quarterly or annual results61
  6. Mar 10, 2022Reported quarterly or annual results62
  7. Nov 10, 2021Reported quarterly or annual results63

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

101 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 33 major events, 28 insider forms, 4 large holders, 1 private raises, 26 other. The latest 20:

  1. Jan 4, 202415-12G EDGAR
  2. Dec 15, 2023DEFA14A EDGAR
  3. Dec 14, 2023425 EDGAR
  4. Dec 14, 20238-K EDGAR
  5. Dec 5, 2023425 EDGAR
  6. Dec 5, 20238-K EDGAR
  7. Nov 16, 2023S-8 POS EDGAR
  8. Nov 16, 2023S-8 POS EDGAR
  9. Nov 16, 2023S-8 POS EDGAR
  10. Nov 16, 2023S-8 POS EDGAR
  11. Nov 14, 2023DEFA14A EDGAR
  12. Nov 9, 202310-Q EDGAR
  13. Oct 18, 2023DEF 14A EDGAR
  14. Oct 4, 2023PRE 14A EDGAR
  15. Oct 3, 20238-K EDGAR
  16. Sep 26, 20238-K EDGAR
  17. Sep 18, 20238-K EDGAR
  18. Aug 15, 20238-K EDGAR
  19. Aug 10, 202310-Q EDGAR
  20. Jul 5, 20238-K EDGAR

The 101 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 14, 2022Raised $5 million in a private offering of securities Form D: 1 investor so far Form D

SEC filer profile

How Histogen Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARHistogen Inc.1
  • CIK0001383701
  • Employer ID (EIN)20-31839151
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address10655 Sorrento Valley Road, Suite 200, San Diego, CA 921211
  • Phone(858) 526-31001
  • Shares outstanding4,271,759 as of Nov 9, 202310
  • Public float$5.4M as of Jun 30, 20224
  • On EDGAR sinceNov 30, 20061
  • Filings552 in all: 4 (162), 8-K (147), 3 (40), 10-Q (32), 425 (18), SC 13G/A (16), SC 13G (15), CORRESP (13)1
    All 40 form types

    10-K (10), DEF 14A (10), UPLOAD (10), 424B5 (9), DEFA14A (8), EFFECT (8), D (5), S-3 (5), S-1/A (4), S-8 (4), S-8 POS (4), 424B3 (3), 4/A (2), 424B4 (2), 5 (2), CT ORDER (2), PRE 14A (2), S-1 (2), S-1MEF (2), S-4/A (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 8-A12B (1), 8-K/A (1), ARS (1), CERTNAS (1), DRS (1), FWP (1), REGDEX (1), REGDEX/A (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Mar 9, 2023
    Quarterly report (10-Q) Nov 9, 2023
    Proxy statement (DEF 14A) Oct 18, 2023
    Latest 8-K (8-K) Dec 14, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65